Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Passage Bio, Inc. (PASG)  
$1.32 0.10 (8.2%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 45,530,000
Market Cap: 60.10(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.6 - $1.73
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Passage Bio is a genetic medicines company focused on developing therapies for monogenic central nervous system disorders. Co. is developing PBGM01, which utilizes a proprietary AAVhu68 capsid for the treatment of GM1 gangliosidosis. Co. is also developing PBFT02, which utilizes an AAV1 capsid for the treatment of frontotemporal dementia-progranulin deficiency. Co. is also developing PBKR03, which utilizes a proprietary AAVhu68 capsid for the treatment of Krabbe disease. Co. has various programs in the research stage under its license agreement with the Trustees of the University of Pennsylvania including: PBML04 for metachromatic leukodystrophy and PBAL05 for amyotrophic lateral sclerosis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 1,192,577 1,717,577
Total Buy Value $0 $0 $1,001,765 $2,018,050
Total People Bought 0 0 1 1
Total Buy Transactions 0 0 2 4
Total Shares Sold 3,108 45,406 56,859 65,593
Total Sell Value $3,015 $41,507 $51,586 $62,246
Total People Sold 2 3 4 6
Total Sell Transactions 2 5 6 9
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 61
  Page 1 of 3  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Borthwick Kathleen SVP, INTERIM CFO   •       –      –    2024-02-13 4 S $0.97 $1,426 D/D (1,470) 28,466 -23%     
   Forman Mark S CHIEF MEDICAL OFFICER   •       –      –    2024-02-13 4 S $0.97 $1,589 D/D (1,638) 48,631 -23%     
   Borthwick Kathleen SVP, INTERIM CFO   •       –      –    2024-02-10 4 OE $0.00 $0 D/D 4,000 29,936     -
   Forman Mark S CHIEF MEDICAL OFFICER   •       –      –    2024-02-10 4 OE $0.00 $0 D/D 5,000 50,269     -
   Borthwick Kathleen SVP, Interim CFO   •       –      –    2024-01-02 4 S $0.91 $9,712 D/D (10,672) 25,936 -35%     
   Forman Mark S Chief Medical Officer   •       –      –    2024-01-02 4 S $0.91 $14,390 D/D (15,813) 45,269 -35%     
   Cale Edgar B. GC & Corporate Secretary   •       –      –    2024-01-02 4 S $0.91 $14,390 D/D (15,813) 45,995 -35%     
   Borthwick Kathleen SVP, Interim CFO   •       –      –    2023-12-31 4 OE $0.00 $0 D/D 30,000 36,608     -
   Forman Mark S Chief Medical Officer   •       –      –    2023-12-31 4 OE $0.00 $0 D/D 50,000 61,082     -
   Cale Edgar B. GC & Corporate Secretary   •       –      –    2023-12-31 4 OE $0.00 $0 D/D 50,000 61,808     -
   King Simona Chief Financial Officer   •       –      –    2023-07-28 4 S $0.88 $10,079 D/D (11,453) 23,994 29%     
   King Simona Chief Financial Officer   •       –      –    2023-07-28 4 OE $0.00 $0 D/D 31,250 35,447     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-06-28 4 B $0.84 $483,164 I/I 575,195 8,034,000 1.5 -20%     
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-06-27 4 B $0.84 $518,601 I/I 617,382 7,458,805 1.5 -18%     
   King Simona Chief Financial Officer   •       –      –    2023-04-18 4 S $1.05 $2,156 D/D (2,053) 2,053 29%     
   King Simona Chief Financial Officer   •       –      –    2023-04-18 4 OE $0.00 $0 D/D 6,250 6,250     -
   Kapadia Sandip Director   –       •      –    2022-12-01 4 AS $1.19 $5,965 D/D (5,000) 0 -10%     
   Toernsen Monika Maria Chief Commercial Officer   •       –      –    2022-09-19 4 S $1.51 $2,539 D/D (1,681) 3,319 9%     
   Toernsen Monika Maria Chief Commercial Officer   •       –      –    2022-09-15 4 OE $0.00 $0 D/D 5,000 5,000     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2022-05-04 4 B $1.94 $588,790 I/I 303,500 6,841,423 1.5 -25%     
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2022-05-03 4 B $1.93 $427,495 I/I 221,500 6,537,923 1.5 -13%     
   Goldsmith Bruce A CEO and President   •       •      –    2022-03-21 4 B $3.15 $31,500 D/D 10,000 15,983 2.81 -39%     
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2022-01-20 4/A B $5.00 $254,000 I/I 50,800 6,316,423 1.5     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2022-01-20 4 B $5.42 $2,000,522 I/I 369,100 6,634,723 1.5 -63%     
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2022-01-19 4 B $5.11 $221,263 I/I 43,300 6,265,623 1.5 -62%     
  61 Records found
  1  2  3   
  Page 1 of 3
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us